Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2020 | May 08, 2020 | |
Document Information [Line Items] | ||
Entity Registrant Name | Avinger Inc | |
Entity Central Index Key | 0001506928 | |
Trading Symbol | avgr | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Current Reporting Status | Yes | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | true | |
Entity Small Business | true | |
Entity Interactive Data Current | Yes | |
Entity Common Stock, Shares Outstanding (in shares) | 31,336,355 | |
Entity Shell Company | false | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2020 | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false | |
Title of 12(b) Security | Common Stock, par value $0.001 per share |
Condensed Balance Sheets (Curre
Condensed Balance Sheets (Current Period Unaudited) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Current assets: | ||
Cash and cash equivalents | $ 9,862,000 | $ 10,943,000 |
Accounts receivable, net of allowance for doubtful accounts of $19 at March 31, 2020 and December 31, 2019 | 1,352,000 | 1,458,000 |
Inventories | 3,875,000 | 3,912,000 |
Prepaid expenses and other current assets | 1,024,000 | 311,000 |
Total current assets | 16,113,000 | 16,624,000 |
Right of use asset | 4,663,000 | 4,856,000 |
Property and equipment, net | 1,387,000 | 1,661,000 |
Other assets | 637,000 | 684,000 |
Total assets | 22,800,000 | 23,825,000 |
Current liabilities: | ||
Accounts payable | 1,385,000 | 663,000 |
Accrued compensation | 1,306,000 | 1,782,000 |
Series A preferred stock dividends payable | 967,000 | |
Accrued expenses and other current liabilities | 695,000 | 654,000 |
Leasehold liability, current portion | 743,000 | 722,000 |
Borrowings, current portion | 9,365,000 | 8,967,000 |
Total current liabilities | 14,461,000 | 12,788,000 |
Leasehold liability, long-term portion | 3,921,000 | 4,135,000 |
Other long-term liabilities | 10,000 | 7,000 |
Total liabilities | 18,392,000 | 16,930,000 |
Commitments and contingencies (Note 6) | ||
Stockholders’ equity: | ||
Convertible preferred stock issuable in series, par value of $0.001, Shares authorized: 5,000,000 at March 31, 2020 and December 31, 2019, Shares issued and outstanding: 48,503 at both March 31, 2020 and December 31, 2019; aggregate liquidation preference of $48,503 at both March 31, 2020 and December 31, 2019, respectively | ||
Common stock, par value of $0.001;, Shares authorized: 100,000,000 at March 31, 2020 and December 31, 2019, Shares issued and outstanding: 16,821,359 and 10,364,663 at March 31, 2020 and December 31, 2019, respectively, | 17,000 | 10,000 |
Additional paid-in capital | 358,577,000 | 355,220,000 |
Accumulated deficit | (354,186,000) | (348,335,000) |
Total stockholders’ equity | 4,408,000 | 6,895,000 |
Total liabilities and stockholders’ equity | $ 22,800,000 | $ 23,825,000 |
Condensed Balance Sheets (Cur_2
Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Accounts receivable, allowance for doubtful accounts | $ 19 | $ 19 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, shares issued (in shares) | 48,503 | 48,503 |
Preferred stock, shares outstanding (in shares) | 48,503 | 48,503 |
Preferred stock, liquidation value | $ 48,503 | $ 48,503 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock, shares issued (in shares) | 16,821,359 | 10,364,663 |
Common stock, shares outstanding (in shares) | 16,821,359 | 10,364,663 |
Condensed Statements of Operati
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Revenues | $ 2,261 | $ 1,840 |
Cost of revenues | 1,760 | 1,467 |
Gross profit | 501 | 373 |
Operating expenses: | ||
Research and development | 1,594 | 1,414 |
Selling, general and administrative | 4,386 | 3,986 |
Total operating expenses | 5,980 | 5,400 |
Loss from operations | (5,479) | (5,027) |
Interest income | 30 | 82 |
Interest expense | (398) | (350) |
Other (expense) income, net | (4) | 240 |
Net loss and comprehensive loss | (5,851) | (5,055) |
Accretion of preferred stock dividends | (967) | (895) |
Net loss attributable to common stockholders | $ (6,818) | $ (5,950) |
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share) | $ (0.47) | $ (1.40) |
Weighted average common shares used to compute net loss per share, basic and diluted (in shares) | 14,616 | 4,248 |
Condensed Statements of Stockho
Condensed Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands | Conversion of Series B Preferred Stock into Common Stock [Member]Preferred Stock [Member] | Conversion of Series B Preferred Stock into Common Stock [Member]Common Stock [Member] | Conversion of Series B Preferred Stock into Common Stock [Member]Additional Paid-in Capital [Member] | Conversion of Series B Preferred Stock into Common Stock [Member]Retained Earnings [Member] | Conversion of Series B Preferred Stock into Common Stock [Member] | Conversion of Series C Preferred Stock into Common Stock [Member]Preferred Stock [Member] | Conversion of Series C Preferred Stock into Common Stock [Member]Common Stock [Member] | Conversion of Series C Preferred Stock into Common Stock [Member]Additional Paid-in Capital [Member] | Conversion of Series C Preferred Stock into Common Stock [Member]Retained Earnings [Member] | Conversion of Series C Preferred Stock into Common Stock [Member] | August Public Offering [Member]Preferred Stock [Member] | August Public Offering [Member]Common Stock [Member] | August Public Offering [Member]Additional Paid-in Capital [Member] | August Public Offering [Member]Retained Earnings [Member] | August Public Offering [Member] | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2018 | 45,671 | 3,492,200 | ||||||||||||||||||
Balance at Dec. 31, 2018 | $ 3 | $ 338,342 | $ (328,885) | $ 9,460 | ||||||||||||||||
Issuance of common stock under officers and directors purchase plan and vesting of restricted stock units (in shares) | 4,689 | |||||||||||||||||||
Issuance of common stock under officers and directors purchase plan and vesting of restricted stock units | 18 | 18 | ||||||||||||||||||
Employee stock-based compensation | 493 | 493 | ||||||||||||||||||
Exercises of warrants for common stock (in shares) | 1,585,160 | |||||||||||||||||||
Exercises of warrants for common stock | $ 2 | 6,338 | 6,340 | |||||||||||||||||
Conversion of convertible securities (in shares) | (1,523) | 380,750 | (2,170) | 542,500 | ||||||||||||||||
Conversion of convertible securities | $ 1 | $ (1) | ||||||||||||||||||
Issuance of Series A preferred stock to pay dividends (in shares) | 2,945 | |||||||||||||||||||
Issuance of Series A preferred stock to pay dividends | 2,918 | 2,918 | ||||||||||||||||||
Accretion of Series A Preferred Stock dividends | (895) | (895) | ||||||||||||||||||
Net and comprehensive loss | (5,055) | (5,055) | ||||||||||||||||||
Balance (in shares) at Mar. 31, 2019 | 44,923 | 6,005,299 | ||||||||||||||||||
Balance at Mar. 31, 2019 | $ 6 | 347,213 | (333,940) | 13,279 | ||||||||||||||||
Balance (in shares) at Dec. 31, 2019 | 48,503 | 10,364,663 | ||||||||||||||||||
Balance at Dec. 31, 2019 | $ 10 | 355,220 | (348,335) | 6,895 | ||||||||||||||||
Issuance of common stock under officers and directors purchase plan and vesting of restricted stock units (in shares) | 28,124 | |||||||||||||||||||
Issuance of common stock under officers and directors purchase plan and vesting of restricted stock units | 18 | 18 | ||||||||||||||||||
Employee stock-based compensation | 451 | 451 | ||||||||||||||||||
Accretion of Series A Preferred Stock dividends | (967) | (967) | ||||||||||||||||||
Net and comprehensive loss | (5,851) | (5,851) | ||||||||||||||||||
Issuance of common stock in public offerings, net of commissions and issuance costs (in shares) | 6,428,572 | |||||||||||||||||||
Issuance of common stock in public offerings, net of commissions and issuance costs | $ 7 | $ 3,855 | $ 3,862 | |||||||||||||||||
Balance (in shares) at Mar. 31, 2020 | 48,503 | 16,821,359 | ||||||||||||||||||
Balance at Mar. 31, 2020 | $ 17 | $ 358,577 | $ (354,186) | $ 4,408 |
Condensed Statements of Cash Fl
Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Cash flows from operating activities | ||
Net loss | $ (5,851) | $ (5,055) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 225 | 200 |
Amortization of debt issuance costs and debt discount | 43 | 43 |
Stock-based compensation | 451 | 493 |
Noncash interest expense and other charges | 434 | 308 |
Provision for excess and obsolete inventories | 104 | 46 |
Other non-cash charges | (1) | |
Changes in operating assets and liabilities: | ||
Accounts receivable | 105 | 42 |
Inventories | (17) | (776) |
Prepaid expenses and other current assets | (722) | (391) |
Other assets | 240 | |
Accounts payable | 722 | (179) |
Accrued compensation | (476) | (181) |
Leasehold liability | (270) | |
Accrued expenses and other current liabilities | 41 | (543) |
Other long-term liabilities | 2 | (3) |
Net cash used in operating activities | (4,970) | (5,996) |
Cash flows from investing activities | ||
Purchase of property and equipment | (83) | |
Proceeds from sale of property and equipment | 18 | |
Net cash used in investing activities | (65) | |
Cash flows from financing activities | ||
Proceeds from the issuance of common stock related to warrant exercises | 6,340 | |
Proceeds from the issuance of common stock under officers and directors purchase plan | 27 | 18 |
Proceeds from the issuance of common stock in public offerings, net | 3,862 | |
Net cash provided by financing activities | 3,889 | 6,358 |
Net change in cash and cash equivalents | (1,081) | 297 |
Cash and cash equivalents, beginning of period | 10,943 | 16,410 |
Cash and cash equivalents, end of period | 9,862 | 16,707 |
Noncash investing and financing activities: | ||
Accretion of Series A preferred stock dividends | 967 | 895 |
Issuance of Series A preferred stock to pay dividends | 2,918 | |
Transfers between inventory and property and equipment | (49) | 198 |
Reclassification of right of use asset to prepaid rent | $ (43) |
Note 1 - Organization
Note 1 - Organization | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Nature of Operations [Text Block] | 1. Organization, Nature of Business Avinger, Inc. (the “Company”), a Delaware corporation, was incorporated in March 2007. “OCT”) March 2016, 510 May 2018, 510 April 2019, July 2019. Liquidity Matters The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014 15, 205 40 one In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of March 31, 2020, $354.2 $9.9 March 31, 2020 third 2020. $3.1 April May 2020, $2.3 $3.9 January 2020 $3.8 August 2019 $8 April May 2019, twelve may The Company can provide no not twelve no 19 19 20%, no 19 may one not Additionally, due to the substantial doubt about the Company’s ability to continue operating as a going concern and the material adverse change clause in the Loan Agreement with CRG Partners III L.P. and certain of its affiliated funds (collectively “CRG”), the entire amount of borrowings at March 31, 2020 December 31, 2019 not Public Offerings On February 16, 2018, 17,979 1,797,900 $15.5 $0.001 no no not one 1 seventh 50 one 2 seventh 60th 50 60 seven April 2019, 60 60 2 seventh 41,800 $38.0 $41.8 2,090,000 On July 12, 2018, 216,618 $16.425 one two 108,309 July 16, 2018, $3.0 $15.80 July 16, 2021. On November 1, 2018, 728,500 8,586 $10.2 $0.001 no On August 26, 2019, 3,813,559 $1.18 $3.8 February 2018 $1.18 On January 31, 2020, 6,428,572 $0.70 $3.9 February 2018 $0.70 On April 30, 2020, 12,600,000 $0.25 May 6, 2020 1,890,000 $3.1 February 2018 $0.25 |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Basis of Presentation and Significant Accounting Policies [Text Block] | 2. Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC (“SEC”). The accompanying unaudited condensed interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company’s financial information. The results for the three March 31, 2020 not December 31, 2020, December 31, 2019 10 December 31, 2019, March 5, 2020. 2 10 December 31, 2019. On June 19, 2019 , 1 - 10 June 21, 2019. not Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its common stock valuation and related stock-based compensation, the valuation of the common stock warrants, the valuation of compound embedded derivatives, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may may Fair Value of Financial Instruments The Company has evaluated the estimated fair value of its financial instruments as of March 31, 2020 December 31, 2019. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three March 31, 2020 December 31, 2019, no March 31, 2020 December 31, 2019. Concentration of Credit Risk, and Other Risks and Uncertainties Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the balance sheets. The Company’s policy is to invest in cash and cash equivalents, consisting of money market funds. These financial instruments are held in Company accounts at one The Company provides for uncollectible amounts when specific credit problems arise. Management’s estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at March 31, 2020 December 31, 2019. The Company’s accounts receivable are due from a variety of healthcare organizations in the United States and select international markets. At March 31, 2020 December 31, 2019, no 10% three March 31, 2020 2019, no 10% The Company manufactures its commercial products in-house, including the Pantheris and Ocelot family of catheters. Certain of the Company’s product components and sub-assemblies continue to be manufactured by sole suppliers, including internally. Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company’s financial position and results of operations. The Company is subject to certain risks, including that its devices may not no not third Existing or future devices developed by the Company may may may Revenue Recognition The Company’s revenues are derived from ( 1 2 3 1. Lightbox sales: The Company sells its products directly to hospitals and medical centers. Provided all other criteria for revenue recognition have been met, the Company recognizes revenue for Lightbox sales directly to end customers when delivery and acceptance occurs, which is defined as receipt by the Company of an executed form by the customer acknowledging that the training and installation process is complete. 2. Sales of disposables: Disposable revenues consist of sales of the Company’s catheters and accessories and are recognized when the product has shipped, risk of loss and title has passed to the customer and collectability is reasonably assured. 3. Service revenue: Service contract revenue is recognized ratably over the term of the service period and maintenance contract revenue is recognized as work is performed. To date, service revenue has been insignificant. The Company offers its customers the ability to purchase or lease its Lightbox. In addition, the Company provides a Lightbox under a limited commercial evaluation program to allow certain strategic accounts to install and utilize the Lightbox for a limited trial period of typically three six The Company evaluates its lease and commercial evaluation program agreements and accounts for these contracts under the guidance in Accounting Standards Codification (“ASC”) 842, Leases No. 2014 09, Revenue from Contracts with Customers (Topic 606 The Company assessed whether the embedded lease is an operating lease or sales-type lease. Based on the Company’s assessment of the guidance and given that any payments under the lease agreements are dependent upon contingent future sales, it was determined that collectability of the minimum lease payments is not not For sales through distributors, the Company recognizes revenue when control of the product transfers from the Company to the distributor. The distributors are responsible for all marketing, sales, training and warranty in their respective territories. The standard terms and conditions contained in the Company’s distribution agreements do not not The Company estimates reductions in revenue for potential returns of products by customers. In making such estimates, management analyzes historical returns, current economic trends and changes in customer demand and acceptance of its products. The Company expenses shipping and handling costs as incurred and includes them in the cost of revenues. When the Company bills shipping and handling costs to customers, such amounts billed are included as a component of revenue. Cost of Revenues Cost of revenues consists primarily of manufacturing overhead costs, material costs and direct labor. A significant portion of the Company’s cost of revenues currently consists of manufacturing overhead costs. These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of revenues also includes depreciation expense for the Lightboxes under lease and evaluation agreements, product warranty costs, product written-off due to excess or obsolescence, and certain direct costs such as shipping costs. Product Warranty Costs The Company typically offers a one Three Months Ended March 31, 2020 2019 Beginning balance $ 215 $ 272 Warranty provision 61 2 Usage/Release (55 ) (68 ) Ending balance $ 221 $ 206 Net Loss per Share Attributable to Common Stockholders Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholder by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Any common stock shares subject to repurchase are excluded from the calculations as the continued vesting of such shares is contingent upon the holders’ continued service to the Company. As of March 31, 2020 2019, no Net loss per share attributable to common stockholders was determined as follows (in thousands, except per share data): Three Months Ended March 31, 20 20 201 9 Net loss attributable to common stockholders $ (6,818 ) $ (5,950 ) Weighted average common stock outstanding, basic and diluted 14,616 4,248 Net loss per share attributable to common stockholders, basic and diluted $ (0.47 ) $ (1.40 ) The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted average shares outstanding because such securities have an anti-dilutive impact due to losses reported: Three Months Ended March 31, 2020 2019 Common stock warrants equivalents 2,753,999 4,503,618 Common stock options 7,267 7,762 Convertible preferred stock 48,503 45,297 Unvested restricted stock units 873,693 289,354 3,683,462 4,846,031 Segment and Geographical Information The Company operates and manages its business as one three March 31, 2020 2019, 98% 91%, Recent Accounting Pronouncements Adopted In February 2016, No. 2016 02, Leases (Topic 842 842 one July, 842 No. 2018 10, Codification Improvements to Topic 842, Leases No. 2018 11, Leases (Topic 842 ): Targeted Improvements January 1, 2019 $1.8 no |
Note 3 - Fair Value Measurement
Note 3 - Fair Value Measurements | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | 3. The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Inputs other than quoted prices included within Level 1 not Level 3 Unobservable inputs that are supported by little or no As of March 31, 2020 December 31, 2019, 1 March 31, 2020 December 31, 2019, no 2 3. no three March 31, 2020. |
Note 4 - Inventories
Note 4 - Inventories | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Inventory Disclosure [Text Block] | 4. Inventories consisted of the following (in thousands): March 31, December 31, 20 20 201 9 Raw materials $ 744 $ 1,426 Work-in-process 873 596 Finished products 2,258 1,890 Total inventories $ 3,875 $ 3,912 |
Note 5 - Borrowings
Note 5 - Borrowings | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 5. CRG On September 22, 2015, $50 March 29, 2017. $30 September 22, 2015. $10 June 15, 2016 On February 14, 2018, $38 $3.8 On March 2, 2020, No. 3 ● extend the period that the Company can make interest payments in payment in kind (PIK) to June 30, 2020; ● lower the Minimum Revenue Covenants to $10 2020, $12 2021, $15 2022; ● insert certain terms to clarify that all fees, including the prepayment premium, are due if the obligations are accelerated; and ● insert a new provision to make clear that to the extent the Company divides its assets/liabilities into divisions, such assets/liabilities will be treated as transferred to a third On May 12, 2020, No. 4 ● grant to the Company the right to optionally prepay in whole or in part the outstanding principal amount of the Loans for the Redemption Price, subject to certain conditions; and ● waive the Company’s requirement to comply with the Minimum Revenue Covenant for 2020. Under the amended Loan Agreement, no third 2021. not 12.5%. third 2021, $1.4 $2.7 2021, $5.5 2022 $2.7 2023. June 30, 3023. The Company may 5.0% 1.0% no seven 1.5% 15.0% The Loan Agreement requires that the Company adheres to certain affirmative and negative covenants, including financial reporting requirements, certain minimum financial covenants for pre-specified liquidity and revenue requirements and a prohibition against the incurrence of indebtedness, or creation of additional liens, other than as specifically permitted by the terms of the Loan Agreement. In particular, the covenants of the amended Loan Agreement included a covenant that the Company maintain a minimum of $3.5 2.0 may As of March 31, 2020, As of March 31, 2020, Period Ending December 31, 2020 (remaining nine months of the year) $ — 2021 3,400 2022 6,266 2023 4,518 14,184 Less: Amount of PIK additions and final facility fee to be incurred subsequent to March 31, 2020 (4,274 ) Less: Amount representing debt financing costs (545 ) Borrowings, as of March 31, 2020 $ 9,365 In connection with drawdowns under the Loan Agreement, the Company recorded aggregate debt discounts of $1.3 March 31, 2020 December 31, 2019, $545,000 $588,000, $43,000 $43,000 three March 31, 2020 2019, three March 31, 2020 2019, $398,000 $350,000, Due to the substantial doubt about the Company’s ability to continue operating as a going concern and the material adverse change clause in the Loan Agreement with CRG, the entire amount of borrowings at March 31, 2020 December 31, 2019 not |
Note 6 - Commitments and Contin
Note 6 - Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 6. Lease Commitments The Company’s operating lease obligations primarily consist of leased office, laboratory, and manufacturing space under a non-cancelable operating lease that originally were to expire in November 2019. On October 19, 2017, one December 1, 2017 November 15, 2019 15 $82,410 Upon the adoption of Topic 842 January 1, 2019, $1.8 On April 1, 2019, five November 30, 2019. November 30, 2024. $5.8 November 2024, December 1, 2019. not In connection with the amendment the Company adjusted its right-of-use asset and lease liability to $6.0 6.5% For the three March 31, 2020, $105,000. three March 31, 2020 2019 $314,000 $492,000, three March 31, 2020 2019 $236,000 $225,000, $419,000 March 31, 2020. The following table presents the future operating lease payments and lease liability included on the balance sheet related to the Company’s operating lease as of March 31, 2020 ( Year Ending December 31, 2020 (remaining nine months of the year) $ 815 2021 1,123 2022 1,162 2023 1,203 2024 1,138 Total 5,441 Less: Imputed interest (777 ) Leasehold liability as of March 31, 2020 $ 4,664 Purchase Obligations Purchase obligations consist of agreements to purchase goods and services entered into in the ordinary course of business. The Company had non-cancelable commitments to suppliers for purchases totaling approximately $1.1 March 31, 2020. Indemnification In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and may may not not The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director is or was serving at the Company’s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws. The term of the indemnification period lasts as long as a director may may not |
Note 7 - Stockholders' Equity
Note 7 - Stockholders' Equity | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 7. Convertible Preferred Stock As of March 31, 2020, 5,000,000 $0.001 48,503 Series A Convertible Preferred Stock On February 14, 2018, $38.0 $3.8 $41.8 2,090,000 8%, no January 2019 December 2019, 2,945 3,580 December 31, 2019. March 31, 2020, 48,325 $967,000 $895,000 March 31, 2020 2019, Series B Convertible Preferred Stock On February 16, 2018, 17,979 $15.5 $0.001 no no not December 31, 2019, 1,523 380,750 March 31, 2020 December 31, 2019, 178 The Company evaluated the Series B convertible preferred stock issuance in accordance with the provisions of ASC 815, Derivatives and Hedging, may $5.2 February 16, 2018. Series C Convertible Preferred Stock On November 1, 2018, 728,500 8,586 $10.2 $0.001 no three March 31, 2019, 2,170 542,500 no Common Stock As of March 31, 2020, 100,000,000 $0.001 16,821,359 Common Stock Warrants In connection with the issuance of the Company’s Series E convertible preferred stock in September 2014 January 2015, 50% September 2, 2019. On February 16, 2018, two 1,797,900 one one $4.00 seventh 50 one seventh 60th 50 60 seven April 2019, 60 60 2 seventh March 31, 2020, 1,768,850 On July 13, 2018, 216,618 108,309 $15.80 one one third March 31, 2020, On November 1, 2018, 728,500 8,586 2,875,000 one one $4.00 5 th one 250 December 31, 2019, 1,998,079 $8.0 March 31, 2020 December 31, 2019, 876,840 As of March 31, 2020 December 31, 2019, 2,753,999 Stock Plans In January 2015, 2015 “2015 2015 2009 “2009 2015 3,300 2015 2015 not 2009 2009 2015 first 2016, 4,225 5.0% 2018, 300,000 2015 June 8, 2018. June 19, 2019, 800,000 2015 March 31, 2020, 123,767 2015 Pursuant to the Plans, ISOs and NSOs may not 100% 10% not 110% four ten Stock option activity under the Plans is set forth below: Number of Weighted Average Price Weighted Average Remaining Contractual Life (in years) Intri n sic Value Balance at December 31, 2019 7,401 $ 1,309.47 6.81 $ — Options expired (205 ) 1,144.02 Options forfeited (1 ) $ 820.00 Balance at March 31, 2020 7,195 $ 1,311.51 6.48 $ — Exercisable at March 31, 2020 7,070 $ 1,320.02 6.47 $ — Vested and expected to vest at March 31, 2020 7,195 $ 1,311.51 6.48 $ — There no three March 31, 2020. March 31, 2020, $39,222 1.0 not three March 31, 2020 2019. The Company’s RSUs generally vest annually over three four Number of Shares Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term Awards outstanding at December 31, 2019 908,504 $ 4.09 1.81 Awarded 47,500 $ 0.58 — Released (86 ) $ 2,171.26 — Forfeited (74,184 ) $ 1.81 — Awards outstanding at March 31, 2020 881,734 $ 3.88 1.63 As of March 31, 2020, $2.5 1.6 881,734 $0.4 $0.42 March 31, 2020, three March 31, 2020 2019, $38 $1,000, no three March 31, 2019. 2018 On August 22, 2018, may may not 20,000 August 28, 2019 March 10, 2020, 40,000 125,000 three March 31, 2020 28,038 March 31, 2020, 117,166 |
Note 8 - Stock-based Compensati
Note 8 - Stock-based Compensation | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | 8. Total noncash stock-based compensation expense relating to the Company’s stock options and RSUs recognized during the three March 31, 2020 2019, Three Months Ended March 31, 20 20 201 9 Cost of revenues $ 34 $ 48 Research and development expenses 132 101 Selling, general and administrative expenses 285 344 $ 451 $ 493 |
Note 9 - Subsequent Events
Note 9 - Subsequent Events | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 9. Paycheck Protection Program On April 23, 2020, $2.3 The Loan, which was in the form of a promissory note, dated April 20, 2020 ( April 20, 2022 1% six may No may The Promissory Note evidencing the PPP Loan contains customary representations, warranties, and covenants for this type of transaction, including customary events of default relating to, among other things, payment defaults and breaches of representations and warranties or other provisions of the Promissory Note. The occurrence of an event of default may Public Offering of Common Stock On April 30, 2020, 12,600,000 $0.25 May 6, 2020 1,890,000 $3.1 February 2018 $0.25 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC (“SEC”). The accompanying unaudited condensed interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company’s financial information. The results for the three March 31, 2020 not December 31, 2020, December 31, 2019 10 December 31, 2019, March 5, 2020. 2 10 December 31, 2019. On June 19, 2019 , 1 - 10 June 21, 2019. not |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its common stock valuation and related stock-based compensation, the valuation of the common stock warrants, the valuation of compound embedded derivatives, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may may |
Fair Value Measurement, Policy [Policy Text Block] | Fair Value of Financial Instruments The Company has evaluated the estimated fair value of its financial instruments as of March 31, 2020 December 31, 2019. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three March 31, 2020 December 31, 2019, no March 31, 2020 December 31, 2019. |
Concentration of Credit Risk and Other Risks and Uncertainties [Policy Text Block] | Concentration of Credit Risk, and Other Risks and Uncertainties Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the balance sheets. The Company’s policy is to invest in cash and cash equivalents, consisting of money market funds. These financial instruments are held in Company accounts at one The Company provides for uncollectible amounts when specific credit problems arise. Management’s estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at March 31, 2020 December 31, 2019. The Company’s accounts receivable are due from a variety of healthcare organizations in the United States and select international markets. At March 31, 2020 December 31, 2019, no 10% three March 31, 2020 2019, no 10% The Company manufactures its commercial products in-house, including the Pantheris and Ocelot family of catheters. Certain of the Company’s product components and sub-assemblies continue to be manufactured by sole suppliers, including internally. Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company’s financial position and results of operations. The Company is subject to certain risks, including that its devices may not no not third Existing or future devices developed by the Company may may may |
Revenue from Contract with Customer [Policy Text Block] | Revenue Recognition The Company’s revenues are derived from ( 1 2 3 1. Lightbox sales: The Company sells its products directly to hospitals and medical centers. Provided all other criteria for revenue recognition have been met, the Company recognizes revenue for Lightbox sales directly to end customers when delivery and acceptance occurs, which is defined as receipt by the Company of an executed form by the customer acknowledging that the training and installation process is complete. 2. Sales of disposables: Disposable revenues consist of sales of the Company’s catheters and accessories and are recognized when the product has shipped, risk of loss and title has passed to the customer and collectability is reasonably assured. 3. Service revenue: Service contract revenue is recognized ratably over the term of the service period and maintenance contract revenue is recognized as work is performed. To date, service revenue has been insignificant. The Company offers its customers the ability to purchase or lease its Lightbox. In addition, the Company provides a Lightbox under a limited commercial evaluation program to allow certain strategic accounts to install and utilize the Lightbox for a limited trial period of typically three six The Company evaluates its lease and commercial evaluation program agreements and accounts for these contracts under the guidance in Accounting Standards Codification (“ASC”) 842, Leases No. 2014 09, Revenue from Contracts with Customers (Topic 606 The Company assessed whether the embedded lease is an operating lease or sales-type lease. Based on the Company’s assessment of the guidance and given that any payments under the lease agreements are dependent upon contingent future sales, it was determined that collectability of the minimum lease payments is not not For sales through distributors, the Company recognizes revenue when control of the product transfers from the Company to the distributor. The distributors are responsible for all marketing, sales, training and warranty in their respective territories. The standard terms and conditions contained in the Company’s distribution agreements do not not The Company estimates reductions in revenue for potential returns of products by customers. In making such estimates, management analyzes historical returns, current economic trends and changes in customer demand and acceptance of its products. The Company expenses shipping and handling costs as incurred and includes them in the cost of revenues. When the Company bills shipping and handling costs to customers, such amounts billed are included as a component of revenue. |
Cost of Goods and Service [Policy Text Block] | Cost of Revenues Cost of revenues consists primarily of manufacturing overhead costs, material costs and direct labor. A significant portion of the Company’s cost of revenues currently consists of manufacturing overhead costs. These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of revenues also includes depreciation expense for the Lightboxes under lease and evaluation agreements, product warranty costs, product written-off due to excess or obsolescence, and certain direct costs such as shipping costs. |
Standard Product Warranty, Policy [Policy Text Block] | Product Warranty Costs The Company typically offers a one Three Months Ended March 31, 2020 2019 Beginning balance $ 215 $ 272 Warranty provision 61 2 Usage/Release (55 ) (68 ) Ending balance $ 221 $ 206 |
Earnings Per Share, Policy [Policy Text Block] | Net Loss per Share Attributable to Common Stockholders Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholder by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Any common stock shares subject to repurchase are excluded from the calculations as the continued vesting of such shares is contingent upon the holders’ continued service to the Company. As of March 31, 2020 2019, no Net loss per share attributable to common stockholders was determined as follows (in thousands, except per share data): Three Months Ended March 31, 20 20 201 9 Net loss attributable to common stockholders $ (6,818 ) $ (5,950 ) Weighted average common stock outstanding, basic and diluted 14,616 4,248 Net loss per share attributable to common stockholders, basic and diluted $ (0.47 ) $ (1.40 ) The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted average shares outstanding because such securities have an anti-dilutive impact due to losses reported: Three Months Ended March 31, 2020 2019 Common stock warrants equivalents 2,753,999 4,503,618 Common stock options 7,267 7,762 Convertible preferred stock 48,503 45,297 Unvested restricted stock units 873,693 289,354 3,683,462 4,846,031 |
Segment Reporting, Policy [Policy Text Block] | Segment and Geographical Information The Company operates and manages its business as one three March 31, 2020 2019, 98% 91%, |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements Adopted In February 2016, No. 2016 02, Leases (Topic 842 842 one July, 842 No. 2018 10, Codification Improvements to Topic 842, Leases No. 2018 11, Leases (Topic 842 ): Targeted Improvements January 1, 2019 $1.8 no |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Notes Tables | |
Schedule of Product Warranty Liability [Table Text Block] | Three Months Ended March 31, 2020 2019 Beginning balance $ 215 $ 272 Warranty provision 61 2 Usage/Release (55 ) (68 ) Ending balance $ 221 $ 206 |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three Months Ended March 31, 20 20 201 9 Net loss attributable to common stockholders $ (6,818 ) $ (5,950 ) Weighted average common stock outstanding, basic and diluted 14,616 4,248 Net loss per share attributable to common stockholders, basic and diluted $ (0.47 ) $ (1.40 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Three Months Ended March 31, 2020 2019 Common stock warrants equivalents 2,753,999 4,503,618 Common stock options 7,267 7,762 Convertible preferred stock 48,503 45,297 Unvested restricted stock units 873,693 289,354 3,683,462 4,846,031 |
Note 4 - Inventories (Tables)
Note 4 - Inventories (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | March 31, December 31, 20 20 201 9 Raw materials $ 744 $ 1,426 Work-in-process 873 596 Finished products 2,258 1,890 Total inventories $ 3,875 $ 3,912 |
Note 5 - Borrowings (Tables)
Note 5 - Borrowings (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | Period Ending December 31, 2020 (remaining nine months of the year) $ — 2021 3,400 2022 6,266 2023 4,518 14,184 Less: Amount of PIK additions and final facility fee to be incurred subsequent to March 31, 2020 (4,274 ) Less: Amount representing debt financing costs (545 ) Borrowings, as of March 31, 2020 $ 9,365 |
Note 6 - Commitments and Cont_2
Note 6 - Commitments and Contingencies (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Notes Tables | |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | Year Ending December 31, 2020 (remaining nine months of the year) $ 815 2021 1,123 2022 1,162 2023 1,203 2024 1,138 Total 5,441 Less: Imputed interest (777 ) Leasehold liability as of March 31, 2020 $ 4,664 |
Note 7 - Stockholders' Equity (
Note 7 - Stockholders' Equity (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Notes Tables | |
Share-based Payment Arrangement, Option, Activity [Table Text Block] | Number of Weighted Average Price Weighted Average Remaining Contractual Life (in years) Intri n sic Value Balance at December 31, 2019 7,401 $ 1,309.47 6.81 $ — Options expired (205 ) 1,144.02 Options forfeited (1 ) $ 820.00 Balance at March 31, 2020 7,195 $ 1,311.51 6.48 $ — Exercisable at March 31, 2020 7,070 $ 1,320.02 6.47 $ — Vested and expected to vest at March 31, 2020 7,195 $ 1,311.51 6.48 $ — |
Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] | Number of Shares Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term Awards outstanding at December 31, 2019 908,504 $ 4.09 1.81 Awarded 47,500 $ 0.58 — Released (86 ) $ 2,171.26 — Forfeited (74,184 ) $ 1.81 — Awards outstanding at March 31, 2020 881,734 $ 3.88 1.63 |
Note 8 - Stock-based Compensa_2
Note 8 - Stock-based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Notes Tables | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | Three Months Ended March 31, 20 20 201 9 Cost of revenues $ 34 $ 48 Research and development expenses 132 101 Selling, general and administrative expenses 285 344 $ 451 $ 493 |
Note 1 - Organization (Details
Note 1 - Organization (Details Textual) - USD ($) | May 06, 2020 | May 06, 2020 | Apr. 30, 2020 | Apr. 23, 2020 | Jan. 31, 2020 | Aug. 26, 2019 | Nov. 01, 2018 | Jul. 12, 2018 | Feb. 16, 2018 | Feb. 14, 2018 | May 31, 2020 | May 31, 2019 | Mar. 31, 2020 | Dec. 31, 2019 | Mar. 31, 2019 | Dec. 31, 2018 | Jul. 13, 2018 |
Retained Earnings (Accumulated Deficit), Ending Balance | $ (354,186,000) | $ (348,335,000) | |||||||||||||||
Cash and Cash Equivalents, at Carrying Value, Ending Balance | $ 9,862,000 | $ 10,943,000 | $ 16,707,000 | $ 16,410,000 | |||||||||||||
Proceeds from Issuance or Sale of Equity, Net | $ 15,500,000 | ||||||||||||||||
Reduction of Non-manufacturing Employees Salaries | 20.00% | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,797,900 | ||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.001 | $ 0.001 | $ 0.001 | ||||||||||||||
Share Price (in dollars per share) | $ 0.42 | ||||||||||||||||
CRG [Member] | Conversion of Principal Amount of Senior Secured Loan to Newly Authorized Series A Preferred Stock [Member] | |||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 38,000,000 | $ 38,000,000 | |||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 41,800,000 | $ 41,800,000 | |||||||||||||||
Common Stock Warrants, Issued with Series B Preferred Stock, Warrant One [Member] | |||||||||||||||||
Class of Warrant or Right, Number of Warrants Issued for Each Share of Preferred Stock (in shares) | 1 | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 50 | ||||||||||||||||
Class of Warrant or Right, Contingent Expiration Period Following Initial Exercise Date (Year) | 7 years | ||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 4 | ||||||||||||||||
Common Stock Warrants, Issued with Series B Preferred Stock, Warrant Two [Member] | |||||||||||||||||
Class of Warrant or Right, Number of Warrants Issued for Each Share of Preferred Stock (in shares) | 1 | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 50 | ||||||||||||||||
Class of Warrant or Right, Contingent Expiration Period Following Initial Exercise Date (Year) | 7 years | ||||||||||||||||
Class of Warrant or Right, Expiration Period Following FDA Clearance (Day) | 60 days | ||||||||||||||||
Series B Preferred Stock [Member] | |||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 17,979 | ||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.001 | ||||||||||||||||
Series A Preferred Stock [Member] | |||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 41,800 | ||||||||||||||||
Series A Preferred Stock [Member] | Conversion of Principal Amount of Senior Secured Loan to Newly Authorized Series A Preferred Stock [Member] | |||||||||||||||||
Convertible Preferred Stock, Shares of Common Stock Issuable on Conversion (in shares) | 2,090,000 | 2,090,000 | |||||||||||||||
Series C Preferred Stock [Member] | |||||||||||||||||
Proceeds from Issuance or Sale of Equity, Net | $ 10,200,000 | ||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 8,586 | ||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.001 | ||||||||||||||||
Subsequent Event [Member] | |||||||||||||||||
Proceeds from Paycheck Protection Program Under CARES Act | $ 2,300,000 | ||||||||||||||||
April and May 2020 Public Offering [Member] | Subsequent Event [Member] | |||||||||||||||||
Proceeds from Issuance or Sale of Equity, Net | $ 3,100,000 | $ 3,100,000 | |||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 1,890,000 | 12,600,000 | |||||||||||||||
Share Price (in dollars per share) | $ 0.25 | ||||||||||||||||
January 2020 Public Offering [Member] | |||||||||||||||||
Proceeds from Issuance or Sale of Equity, Net | $ 3,900,000 | ||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 6,428,572 | ||||||||||||||||
Share Price (in dollars per share) | $ 0.70 | ||||||||||||||||
August Public Offering [Member] | |||||||||||||||||
Proceeds from Issuance or Sale of Equity, Net | $ 3,800,000 | ||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 3,813,559 | ||||||||||||||||
Share Price (in dollars per share) | $ 1.18 | ||||||||||||||||
April and May Offering [Member] | |||||||||||||||||
Proceeds from Issuance or Sale of Equity, Net | $ 8,000,000 | ||||||||||||||||
Placement Agency Sale - Prospectus Supplement of July 12, 2018 [Member] | |||||||||||||||||
Sale of Stock, Consideration Received on Transaction | $ 3,000,000 | ||||||||||||||||
Placement Agency Sale - Prospectus Supplement of July 12, 2018 [Member] | Common Stock Warrants [Member] | |||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 216,618 | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 108,309 | 108,309 | |||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | ||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 16.425 | ||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 15.80 | $ 15.80 | |||||||||||||||
November Public Offering [Member] | |||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 728,500 | ||||||||||||||||
November Public Offering [Member] | Common Stock Warrants [Member] | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 2,875,000 | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | ||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 4 | ||||||||||||||||
November Public Offering [Member] | Series C Preferred Stock [Member] | |||||||||||||||||
Proceeds from Issuance or Sale of Equity, Net | $ 10,200,000 | ||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 8,586 |
Note 2 - Summary of Significa_3
Note 2 - Summary of Significant Accounting Policies (Details Textual) shares in Thousands | Jun. 19, 2019 | Mar. 31, 2020USD ($)shares | Mar. 31, 2019shares | Dec. 31, 2019USD ($) | Apr. 01, 2019USD ($) | Jan. 01, 2019USD ($) |
Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax, Total | $ 0 | $ 0 | ||||
Warranty Period (Year) | 1 year | |||||
Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation (in shares) | shares | 0 | 0 | ||||
Number of Reportable Segments | 1 | |||||
Operating Lease, Right-of-Use Asset | $ 4,663,000 | $ 4,856,000 | $ 6,000,000 | |||
Operating Lease, Liability, Total | $ 4,664,000 | $ 6,000,000 | ||||
Accounting Standards Update 2016-02 [Member] | ||||||
Operating Lease, Right-of-Use Asset | $ 1,800,000 | |||||
Operating Lease, Liability, Total | $ 1,800,000 | |||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | ||||||
Number of Major Customers | 0 | 0 | ||||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | ||||||
Number of Major Customers | 0 | 0 | ||||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | UNITED STATES | ||||||
Concentration Risk, Percentage | 98.00% | 91.00% | ||||
Reverse Stock Split [Member] | ||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 10 |
Note 2 - Summary of Significa_4
Note 2 - Summary of Significant Accounting Policies - Product Warranty (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Beginning balance | $ 215 | $ 272 |
Warranty provision | 61 | 2 |
Usage/Release | (55) | (68) |
Ending balance | $ 221 | $ 206 |
Note 2 - Summary of Significa_5
Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Net loss attributable to common stockholders | $ (6,818) | $ (5,950) |
Weighted average common stock outstanding, basic and diluted (in shares) | 14,616 | 4,248 |
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share) | $ (0.47) | $ (1.40) |
Note 2 - Summary of Significa_6
Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Antidilutive Securities (in shares) | 3,683,462 | 4,846,031 |
Common Stock Warrants [Member] | ||
Antidilutive Securities (in shares) | 2,753,999 | 4,503,618 |
Common Stock Options [ member] | ||
Antidilutive Securities (in shares) | 7,267 | 7,762 |
Preferred Stock [Member] | ||
Antidilutive Securities (in shares) | 48,503 | 45,297 |
Restricted Stock Units (RSUs) [Member] | ||
Antidilutive Securities (in shares) | 873,693 | 289,354 |
Note 3 - Fair Value Measureme_2
Note 3 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Fair Value, Inputs, Level 2 [Member] | ||
Assets, Fair Value Disclosure | $ 0 | $ 0 |
Financial and Nonfinancial Liabilities, Fair Value Disclosure | 0 | 0 |
Fair Value, Inputs, Level 3 [Member] | ||
Assets, Fair Value Disclosure | 0 | 0 |
Financial and Nonfinancial Liabilities, Fair Value Disclosure | $ 0 | $ 0 |
Note 4 - Inventories - Schedule
Note 4 - Inventories - Schedule of Inventory (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Raw materials | $ 744 | $ 1,426 |
Work-in-process | 873 | 596 |
Finished products | 2,258 | 1,890 |
Total inventories | $ 3,875 | $ 3,912 |
Note 5 - Borrowings (Details Te
Note 5 - Borrowings (Details Textual) | Feb. 14, 2018USD ($) | Mar. 31, 2020USD ($) | Mar. 31, 2019USD ($) | Dec. 31, 2021USD ($) | Dec. 31, 2023USD ($) | Dec. 31, 2022USD ($) | Mar. 02, 2020USD ($) | Dec. 31, 2019USD ($) | Jun. 15, 2016USD ($) | Sep. 22, 2015USD ($) |
Line of Credit Facility, Maximum Borrowing Capacity | $ 50,000,000 | |||||||||
Debt Instrument, Covenant Compliance Target Minimum Revenue, Next Twelve Months | $ 10,000,000 | |||||||||
Debt Instrument, Covenant, Compliance Target Minimum Revenue Second Year | 12,000,000 | |||||||||
Debt Instrument, Covenant Compliance Target Minimum Revenue Third Year | $ 15,000,000 | |||||||||
Debt Instrument, Redemption Initial Prepayment Premium Percentage | 5.00% | |||||||||
Debt Instrument, Redemption Annual Decline in Prepayment Premium Percentage | 1.00% | |||||||||
Debt Instrument, Redemption Prepayment Premium Percentage after Fifth Year | 0.00% | |||||||||
Debt Instrument, Financing Fee Percentage | 1.50% | |||||||||
Debt Instrument, Final Facility Fee Percentage | 15.00% | |||||||||
Debt Instrument, Covenant Compliance Cash and Certain Cash Equivalents Minimum | $ 3,500,000 | |||||||||
Debt Instrument, Covenant Compliance Prepayment Multiplier for Revenue Shortfall | 2 | |||||||||
Interest Expense, Total | $ 398,000 | $ 350,000 | ||||||||
CRG [Member] | Loan Agreement [Member] | ||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total | 545,000 | $ 588,000 | $ 1,300,000 | |||||||
Amortization of Debt Discount (Premium) | 43,000 | 43,000 | ||||||||
Interest Expense, Total | $ 398,000 | $ 350,000 | ||||||||
CRG [Member] | Loan Agreement [Member] | Forecast [Member] | ||||||||||
Debt Instrument, Periodic Payment, Principal | $ 1,400,000 | |||||||||
Debt Instrument, Periodic Payment, Total | $ 2,700,000 | $ 2,700,000 | $ 5,500,000 | |||||||
CRG [Member] | Loan Agreement [Member] | Series A Preferred Stock Purchase Agreement with CRG [Member] | ||||||||||
Debt Conversion, Original Debt, Amount | $ 38,000,000 | |||||||||
Debt Conversion, Fees and Prepayment Premium Amount | $ 3,800,000 | |||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.50% | |||||||||
CRG [Member] | Loan Agreement [Member] | First Tranche, Borrowed on September 22, 2015 [Member] | ||||||||||
Debt Instrument, Face Amount | $ 30,000,000 | |||||||||
CRG [Member] | Loan Agreement [Member] | Second Tranche, Borrowed on June 15, 2016 [Member] | ||||||||||
Debt Instrument, Face Amount | $ 10,000,000 |
Note 5 - Borrowings - Schedule
Note 5 - Borrowings - Schedule of Debt (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Borrowings, as of March 31, 2020 | $ 9,365 | $ 8,967 |
CRG [Member] | Loan Agreement [Member] | ||
2020 (remaining nine months of the year) | ||
2021 | 3,400 | |
2022 | 6,266 | |
2023 | 4,518 | |
Long-term Debt, Total | 14,184 | |
Less: Amount of PIK additions and final facility fee to be incurred subsequent to March 31, 2020 | (4,274) | |
Less: Amount representing debt financing costs | (545) | |
Borrowings, as of March 31, 2020 | $ 9,365 |
Note 6 - Commitments and Cont_3
Note 6 - Commitments and Contingencies (Details Textual) - USD ($) | Dec. 01, 2017 | Mar. 31, 2021 | Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | Apr. 01, 2019 | Jan. 01, 2019 |
Operating Lease, Right-of-Use Asset | $ 4,663,000 | $ 4,856,000 | $ 6,000,000 | ||||
Operating Lease, Liability, Total | 4,664,000 | $ 6,000,000 | |||||
Lessee, Operating Lease, Term of Contract (Year) | 5 years | ||||||
Lessee, Operating Lease, Liability, Payments, Due, Total | 5,441,000 | $ 5,800,000 | |||||
Lessee, Operating Lease, Discount Rate | 6.50% | ||||||
Operating Lease, Expense | 314,000 | $ 492,000 | |||||
Operating Lease, Right-of-Use Asset, Amortization Expense | 236,000 | $ 225,000 | |||||
Prepaid Rent | 419,000 | ||||||
Purchase Commitment [Member] | |||||||
Purchase Obligation, Total | $ 1,100,000 | ||||||
Forecast [Member] | |||||||
Operating Lease, Expense | $ 105,000 | ||||||
Accounting Standards Update 2016-02 [Member] | |||||||
Operating Lease, Right-of-Use Asset | $ 1,800,000 | ||||||
Operating Lease, Liability, Total | $ 1,800,000 | ||||||
Facility Sublease [Member] | |||||||
Operating Leases Sublease Expiration Prior to Base Lease (Day) | 15 days | ||||||
Operating Leases, Monthly Minimum Sublease Rental Payments Receivable Final | $ 82,410 |
Note 6 - Commitments and Cont_4
Note 6 - Commitments and Contingencies - Future Operating Lease Payments (Details) - USD ($) | Mar. 31, 2020 | Apr. 01, 2019 |
2020 (remaining nine months of the year) | $ 815,000 | |
2021 | 1,123,000 | |
2022 | 1,162,000 | |
2023 | 1,203,000 | |
2024 | 1,138,000 | |
Total | 5,441,000 | $ 5,800,000 |
Less: Imputed interest | (777,000) | |
Leasehold liability as of March 31, 2020 | $ 4,664,000 | $ 6,000,000 |
Note 7 - Stockholders' Equity_2
Note 7 - Stockholders' Equity (Details Textual) - USD ($) | Jun. 19, 2019 | Nov. 01, 2018 | Jul. 13, 2018 | Jul. 12, 2018 | Feb. 16, 2018 | Feb. 14, 2018 | Dec. 31, 2019 | Jan. 31, 2019 | Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | Mar. 10, 2020 | Aug. 28, 2019 | Aug. 22, 2018 | Jan. 31, 2015 |
Preferred Stock, Shares Authorized (in shares) | 5,000,000 | 5,000,000 | 5,000,000 | |||||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | ||||||||||||
Preferred Stock, Shares Issued, Total (in shares) | 48,503 | 48,503 | 48,503 | |||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 48,503 | 48,503 | 48,503 | |||||||||||||
Proceeds from Issuance or Sale of Equity, Net | $ 15,500,000 | |||||||||||||||
Common Stock, Shares Authorized (in shares) | 100,000,000 | 100,000,000 | 100,000,000 | |||||||||||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.001 | $ 0.001 | $ 0.001 | |||||||||||||
Common Stock, Shares, Issued, Total (in shares) | 10,364,663 | 16,821,359 | 10,364,663 | |||||||||||||
Common Stock, Shares, Outstanding, Ending Balance (in shares) | 10,364,663 | 16,821,359 | 10,364,663 | |||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,797,900 | |||||||||||||||
Proceeds from Warrant Exercises | $ 6,340,000 | |||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 2,753,999 | 2,753,999 | 2,753,999 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 4 years | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | |||||||||||||||
Share-based Payment Arrangement, Expense, Tax Benefit | $ 0 | 0 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares) | 0 | |||||||||||||||
Share Price (in dollars per share) | $ 0.42 | |||||||||||||||
Share-based Payment Arrangement, Option [Member] | ||||||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 39,222 | |||||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 1 year | |||||||||||||||
Restricted Stock Units (RSUs) [Member] | ||||||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 2,500,000 | |||||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 1 year 219 days | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares) | 908,504 | 881,734 | 908,504 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Fair Value | $ 400,000 | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value | $ 38 | $ 1,000 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 47,500 | 0 | ||||||||||||||
Minimum [Member] | Common Stock Options [ member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent | 100.00% | |||||||||||||||
Minimum [Member] | Common Stock Options [ member] | Stockholder with More than 10% Voting Power [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent | 110.00% | |||||||||||||||
Minimum [Member] | Restricted Stock Units (RSUs) [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 3 years | |||||||||||||||
Maximum [Member] | Restricted Stock Units (RSUs) [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 4 years | |||||||||||||||
The 2015 Employee Stock Purchase Plan [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 3,300 | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Reserved for Issuance, Annual (in shares) | 4,225 | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Reserved for Issuance, Percentage on Shares Outstanding | 5.00% | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares) | 800,000 | 300,000 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) | 123,767 | |||||||||||||||
Officer and Director Share Purchase Plan [Member] | ||||||||||||||||
Common Stock, Shares, Issued, Total (in shares) | 28,038 | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 125,000 | 40,000 | 20,000 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) | 117,166 | |||||||||||||||
November Public Offering [Member] | ||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 728,500 | |||||||||||||||
Common Stock Warrants, Issued with Series E Convertible Preferred Stock [Member] | ||||||||||||||||
Class of Warrant or Right, Securities Called as Percentage of Convertible Preferred Stock Shares | 50.00% | |||||||||||||||
Common Stock Warrants, Issued with Series B Preferred Stock [Member] | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,797,900 | 1,768,850 | ||||||||||||||
Common Stock Warrants, Issued with Series B Preferred Stock, Warrant One [Member] | ||||||||||||||||
Class of Warrant or Right, Number of Warrants Issued for Each Share of Preferred Stock (in shares) | 1 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 4 | |||||||||||||||
Class of Warrant or Right, Contingent Expiration Period Following Initial Exercise Date (Year) | 7 years | |||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 50 | |||||||||||||||
Common Stock Warrants, Issued with Series B Preferred Stock, Warrant Two [Member] | ||||||||||||||||
Class of Warrant or Right, Number of Warrants Issued for Each Share of Preferred Stock (in shares) | 1 | |||||||||||||||
Class of Warrant or Right, Contingent Expiration Period Following Initial Exercise Date (Year) | 7 years | |||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 50 | |||||||||||||||
Class of Warrant or Right, Expiration Period Following FDA Clearance (Day) | 60 days | |||||||||||||||
Common Stock Warrants [Member] | Placement Agency Sale - Prospectus Supplement of July 12, 2018 [Member] | ||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 216,618 | |||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 108,309 | 108,309 | ||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 15.80 | $ 15.80 | ||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||
Common Stock Warrants [Member] | November Public Offering [Member] | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 2,875,000 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 4 | |||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||
Class of Warrant or Right, Exercised (in shares) | 1,998,079 | |||||||||||||||
Proceeds from Warrant Exercises | $ 8,000,000 | |||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 876,840 | 876,840 | 876,840 | |||||||||||||
Preferred Stock Warrants [Member] | November Public Offering [Member] | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 250 | |||||||||||||||
Common Stock [Member] | ||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 728,500 | |||||||||||||||
Common Stock [Member] | Placement Agency Sale - Prospectus Supplement of July 12, 2018 [Member] | ||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 216,618 | |||||||||||||||
Common Stock [Member] | November Public Offering [Member] | ||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 728,500 | |||||||||||||||
Conversion of Series B Preferred Stock into Common Stock [Member] | ||||||||||||||||
Conversion of Stock, Shares Converted (in shares) | 1,523 | |||||||||||||||
Conversion of Stock, Shares Issued (in shares) | 380,750 | |||||||||||||||
Conversion of Series C Preferred Stock into Common Stock [Member] | ||||||||||||||||
Conversion of Stock, Shares Issued (in shares) | 542,500 | |||||||||||||||
Series A Preferred Stock [Member] | ||||||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 48,325 | |||||||||||||||
Dividends, Preferred Stock, Total | $ 967,000 | $ 895,000 | ||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 41,800 | |||||||||||||||
Series A Preferred Stock [Member] | CRG [Member] | ||||||||||||||||
Preferred Stock Dividends, Shares (in shares) | 3,580 | 2,945 | ||||||||||||||
Series B Preferred Stock [Member] | ||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.001 | |||||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 178 | 178 | 178 | |||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 17,979 | |||||||||||||||
Preferred Stock Deemed Dividend Arising from Beneficial Conversion Feature | $ 5,200,000 | |||||||||||||||
Series C Preferred Stock [Member] | ||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.001 | |||||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 2,170 | |||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 8,586 | |||||||||||||||
Proceeds from Issuance or Sale of Equity, Net | $ 10,200,000 | |||||||||||||||
Series C Preferred Stock [Member] | November Public Offering [Member] | ||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 8,586 | |||||||||||||||
Proceeds from Issuance or Sale of Equity, Net | $ 10,200,000 | |||||||||||||||
Conversion of Principal Amount of Senior Secured Loan to Newly Authorized Series A Preferred Stock [Member] | Series A Preferred Stock [Member] | ||||||||||||||||
Convertible Preferred Stock, Shares of Common Stock Issuable on Conversion (in shares) | 2,090,000 | 2,090,000 | ||||||||||||||
Preferred Stock, Dividend Rate, Percentage | 8.00% | |||||||||||||||
CRG [Member] | Conversion of Principal Amount of Senior Secured Loan to Newly Authorized Series A Preferred Stock [Member] | ||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 38,000,000 | $ 38,000,000 | ||||||||||||||
Debt Conversion, Fees and Prepayment Premium Amount | 3,800,000 | |||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 41,800,000 | $ 41,800,000 |
Note 7 - Stockholders' Equity -
Note 7 - Stockholders' Equity - Stock Option Activity (Details) - $ / shares shares in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2020 | Dec. 31, 2019 | |
Options (in shares) | 7,401 | |
Options, weighted average exercise price (in dollars per share) | $ 1,309.47 | |
Balance, weighted average remaining contractual life (Year) | 6 years 175 days | 6 years 295 days |
Options expired (in shares) | (205) | |
Options expired, weighted average exercise price (in dollars per share) | $ 1,144.02 | |
Options forfeited (in shares) | (1) | |
Options forfeited, weighted average exercise price (in dollars per share) | $ 820 | |
Options (in shares) | 7,195 | 7,401 |
Options, weighted average exercise price (in dollars per share) | $ 1,311.51 | $ 1,309.47 |
Exercisable (in shares) | 7,070 | |
Exercisable, weighted average exercise price (in dollars per share) | $ 1,320.02 | |
Exercisable, weighted average remaining contractual life (Year) | 6 years 171 days | |
Vested and expected to vest (in shares) | 7,195 | |
Vested and expected to vest, weighted average exercise price (in dollars per share) | $ 1,311.51 | |
Vested and expected to vest, weighted average remaining contractual life (Year) | 6 years 175 days |
Note 7 - Stockholders' Equity_3
Note 7 - Stockholders' Equity - Restricted Stock Units Award Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | |
Awards outstanding, Shares (in shares) | 908,504 | ||
Awards outstanding, Weighted grant date fair value (in dollars per share) | $ 4.09 | ||
Awards outstanding, Weighted average remaining contractual term (Year) | 1 year 229 days | 1 year 295 days | |
Awarded, Shares (in shares) | 47,500 | 0 | |
Awarded, Weighted grant date fair value (in dollars per share) | $ 0.58 | ||
Released, Shares (in shares) | (86) | ||
Released, Weighted grant date fair value (in dollars per share) | $ 2,171.26 | ||
Forfeited, Shares (in shares) | (74,184) | ||
Forfeited, Weighted grant date fair value (in dollars per share) | $ 1.81 | ||
Awards outstanding, Shares (in shares) | 881,734 | 908,504 | |
Awards outstanding, Weighted grant date fair value (in dollars per share) | $ 3.88 | $ 4.09 |
Note 8 - Stock-based Compensa_3
Note 8 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Allocated Share-based Compensation Expense | $ 451 | $ 493 |
Cost of Sales [Member] | ||
Allocated Share-based Compensation Expense | 34 | 48 |
Research and Development Expense [Member] | ||
Allocated Share-based Compensation Expense | 132 | 101 |
Selling, General and Administrative Expenses [Member] | ||
Allocated Share-based Compensation Expense | $ 285 | $ 344 |
Note 9 - Subsequent Events (Det
Note 9 - Subsequent Events (Details Textual) - USD ($) $ / shares in Units, $ in Millions | May 06, 2020 | May 06, 2020 | Apr. 30, 2020 | Apr. 23, 2020 | Feb. 16, 2018 | May 31, 2020 | Mar. 31, 2020 |
Share Price (in dollars per share) | $ 0.42 | ||||||
Proceeds from Issuance or Sale of Equity, Net | $ 15.5 | ||||||
Subsequent Event [Member] | |||||||
Proceeds from Paycheck Protection Program Under CARES Act | $ 2.3 | ||||||
Subsequent Event [Member] | April and May 2020 Public Offering [Member] | |||||||
Stock Issued During Period, Shares, New Issues (in shares) | 1,890,000 | 12,600,000 | |||||
Share Price (in dollars per share) | $ 0.25 | ||||||
Proceeds from Issuance or Sale of Equity, Net | $ 3.1 | $ 3.1 |